Antibody therapeutics represents a growing and very successful class of drugs with applications in diverse therapeutic areas like cancer, autoimmunity, inflammation, osteoporosis, cardiometabol-ic, ophthalmic and infectious diseases. Of the numerous antibodies generated in preclinical development, currently over 200 are in clinical trials and 30 of these have progressed to the final stages of development [1 ]. As of September 2013, 35 antibodies were approved as human therapeutics.
展开▼
